Clinical Trial

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the effect of capivasertib on the pharmacokinetics of oral dextromethorphan in healthy participants.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-28
notable Primary completion pushed: 2026-06-17 -> 2026-07-20 2026-07-28
minor Completion pushed: 2026-06-17 -> 2026-07-20 2026-07-28
Trial Details
NCT Number NCT07241065
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Healthy Participants
Enrollment 42 participants
Start Date 2026-03-19
Primary Completion 2026-07-20 (estimated)
Study Completion 2026-07-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-27